AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 2.33 |
Market Cap | 86.92M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -0.26 |
PE Ratio (ttm) | -9.08 |
Forward PE | n/a |
Analyst | Buy |
Ask | 2.45 |
Volume | 13,772 |
Avg. Volume (20D) | 129,062 |
Open | 2.48 |
Previous Close | 2.40 |
Day's Range | 2.35 - 2.48 |
52-Week Range | 0.68 - 3.35 |
Beta | undefined |
About ENTX
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials fo...
Analyst Forecast
According to 1 analyst ratings, the average rating for ENTX stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 323.73% from the latest price.
Next Earnings Release
Analysts project revenue of $40.00K, reflecting a n/a YoY growth and earnings per share of -0.08, making a 14.29% increase YoY.